Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Operating Leases: 2019-2024

Historic Operating Leases for Intellia Therapeutics (NTLA) over the last 6 years, with Dec 2024 value amounting to $190.0 million.

  • Intellia Therapeutics' Operating Leases fell 14.38% to $70.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.6 million, marking a year-over-year decrease of 14.38%. This contributed to the annual value of $190.0 million for FY2024, which is 96.34% up from last year.
  • According to the latest figures from FY2024, Intellia Therapeutics' Operating Leases is $190.0 million, which was up 96.34% from $96.7 million recorded in FY2023.
  • Intellia Therapeutics' 5-year Operating Leases high stood at $190.0 million for FY2024, and its period low was $33.6 million during FY2020.
  • Over the past 3 years, Intellia Therapeutics' median Operating Leases value was $114.0 million (recorded in 2022), while the average stood at $133.6 million.
  • As far as peak fluctuations go, Intellia Therapeutics' Operating Leases spiked by 166.10% in 2020, and later declined by 15.15% in 2023.
  • Intellia Therapeutics' Operating Leases (Yearly) stood at $33.6 million in 2020, then spiked by 93.14% to $64.9 million in 2021, then spiked by 75.65% to $114.0 million in 2022, then decreased by 15.15% to $96.7 million in 2023, then spiked by 96.34% to $190.0 million in 2024.